Based on the ResMed Inc stock forecast from 9 analysts, the average analyst target price for ResMed Inc is USD 241.29 over the next 12 months. ResMed Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of ResMed Inc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, ResMed Inc’s stock price was USD 243.60. ResMed Inc’s stock price has changed by +5.26% over the past week, +1.48% over the past month and +59.62% over the last year.
No recent analyst target price found for ResMed Inc
No recent average analyst rating found for ResMed Inc
Company Overview ResMed Inc
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. Read Less
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for...Read More
Frequently Asked Questions About ResMed Inc (RMD) Stock
Based on ratings from 9 analysts ResMed Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 10 buy, 1 sell and 6 hold ratings.
RMD stock's dividend yield is 0.87%.
Our analysis grades RMD stock's dividend yield at F. This means that RMD stock's dividend yield is above 56% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this RMD may be a average dividend stock for its sector.
Based on targets from 9 analysts, the average taret price for RMD is USD 241.29 over the next 12 months. The maximum analyst target price is USD 280 while the minimum anlayst target price is USD 180.
RMD stock's Price/Earning ratio is 32.36.
Our analysis grades RMD stock's Price / Earning ratio at A-. This means that RMD stock's Price/Earning ratio is above 7.999999999999996% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this RMD may be undervalued for its sector.
The last closing price of RMD's stock was USD 243.60.
The most recent market capitalization for RMD is USD 35.86B.
Based on targets from 9 analysts, the average taret price for RMD is projected at USD 241.29 over the next 12 months.
This means that RMD's stock price may go down by -0.95% over the next 12 months.
We can't find any ETFs which contains ResMed Inc's stock.
As per our most recent records ResMed Inc has 0 Employees.
ResMed Inc's registered address is 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123.
You can get more information about it from ResMed Inc's website at https://www.resmed.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ResMed Inc (RMD) Stock
Based on ratings from 9 analysts ResMed Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 10 buy, 1 sell and 6 hold ratings.
RMD stock's dividend yield is 0.87%.
Our analysis grades RMD stock's dividend yield at F. This means that RMD stock's dividend yield is above 56% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this RMD may be a average dividend stock for its sector.
Based on targets from 9 analysts, the average taret price for RMD is USD 241.29 over the next 12 months. The maximum analyst target price is USD 280 while the minimum anlayst target price is USD 180.
RMD stock's Price/Earning ratio is 32.36.
Our analysis grades RMD stock's Price / Earning ratio at A-. This means that RMD stock's Price/Earning ratio is above 7.999999999999996% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this RMD may be undervalued for its sector.
The last closing price of RMD's stock was USD 243.60.
The most recent market capitalization for RMD is USD 35.86B.
Based on targets from 9 analysts, the average taret price for RMD is projected at USD 241.29 over the next 12 months.
This means that RMD's stock price may go down by -0.95% over the next 12 months.
We can't find any ETFs which contains ResMed Inc's stock.
As per our most recent records ResMed Inc has 0 Employees.
ResMed Inc's registered address is 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123.
You can get more information about it from ResMed Inc's website at https://www.resmed.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RMD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
